000276798 001__ 276798
000276798 005__ 20250323000844.0
000276798 0247_ $$2doi$$a10.1111/epi.18200
000276798 0247_ $$2pmid$$apmid:39607395
000276798 0247_ $$2pmc$$apmc:PMC11827734
000276798 0247_ $$2ISSN$$a0013-9580
000276798 0247_ $$2ISSN$$a1528-1167
000276798 0247_ $$2altmetric$$aaltmetric:171522088
000276798 037__ $$aDZNE-2025-00323
000276798 041__ $$aEnglish
000276798 082__ $$a610
000276798 1001_ $$00009-0000-3445-6397$$aEberhard, Judith$$b0
000276798 245__ $$aAblation of CCL17-positive hippocampal neurons induces inflammation-dependent epilepsy.
000276798 260__ $$aOxford [u.a.]$$bWiley-Blackwell$$c2025
000276798 3367_ $$2DRIVER$$aarticle
000276798 3367_ $$2DataCite$$aOutput Types/Journal article
000276798 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1739955215_3108
000276798 3367_ $$2BibTeX$$aARTICLE
000276798 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000276798 3367_ $$00$$2EndNote$$aJournal Article
000276798 520__ $$aNeuronal cell death and neuroinflammation are characteristic features of epilepsy, but it remains unclear whether neuronal cell death as such is causative for the development of epileptic seizures. To test this hypothesis, we established a novel mouse line permitting inducible ablation of pyramidal neurons by inserting simian diphtheria toxin (DT) receptor (DTR) cDNA into the Ccl17 locus. The chemokine CCL17 is expressed in pyramidal CA1 neurons in adult mice controlling microglial quiescence.Seizure activity in CCL17-DTR mice was analyzed by electroencephalographic recordings following treatment with DT for 3 consecutive days. Neuroinflammation and neuronal cell death were evaluated by (immuno)histochemistry. Pharmacological inhibition of TNFR1 signaling was achieved by treatment with XPro1595, a dominant-negative inhibitor of soluble tumor necrosis factor.Neuronal cell death was detectable 7 days (d7) after the first DT injection in heterozygous CCL17-DTR mice. Spontaneous epileptic seizures were observed in the vast majority of mice, often with an initial peak at d6-9, followed by a period of reduced activity and a gradual increase during the 1-month observation period. Microglial reactivity was overt from d5 after DT administration not only in the CA1 region but also in the CA2/CA3 area, shortly followed by astrogliosis. Reactive microgliosis and astrogliosis persisted until d30 and, together with neuronal loss and stratum radiatum shrinkage, reflected important features of human hippocampal sclerosis. Granule cell dispersion was detectable only 3 months after DT treatment. Application of XPro1595 significantly reduced chronic seizure burden without affecting the development of hippocampal sclerosis.In conclusion, our data demonstrate that sterile pyramidal neuronal death is sufficient to cause epilepsy in the absence of other pathological processes. The CCL17-DTR mouse line may thus be a valuable model for further mechanistic studies on epilepsy and assessment of antiseizure medication.
000276798 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000276798 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000276798 650_7 $$2Other$$aXPro1595
000276798 650_7 $$2Other$$aastrogliosis
000276798 650_7 $$2Other$$adiphtheria toxin
000276798 650_7 $$2Other$$amicrogliosis
000276798 650_7 $$2Other$$aneurodegeneration
000276798 650_7 $$2NLM Chemicals$$aChemokine CCL17
000276798 650_7 $$2NLM Chemicals$$aCcl17 protein, mouse
000276798 650_2 $$2MeSH$$aAnimals
000276798 650_2 $$2MeSH$$aMice
000276798 650_2 $$2MeSH$$aEpilepsy: pathology
000276798 650_2 $$2MeSH$$aEpilepsy: drug therapy
000276798 650_2 $$2MeSH$$aHippocampus: pathology
000276798 650_2 $$2MeSH$$aHippocampus: drug effects
000276798 650_2 $$2MeSH$$aHippocampus: metabolism
000276798 650_2 $$2MeSH$$aNeurons: drug effects
000276798 650_2 $$2MeSH$$aNeurons: pathology
000276798 650_2 $$2MeSH$$aNeurons: metabolism
000276798 650_2 $$2MeSH$$aMice, Transgenic
000276798 650_2 $$2MeSH$$aChemokine CCL17: genetics
000276798 650_2 $$2MeSH$$aChemokine CCL17: metabolism
000276798 650_2 $$2MeSH$$aElectroencephalography
000276798 650_2 $$2MeSH$$aCell Death: drug effects
000276798 650_2 $$2MeSH$$aMice, Inbred C57BL
000276798 650_2 $$2MeSH$$aMale
000276798 650_2 $$2MeSH$$aDisease Models, Animal
000276798 650_2 $$2MeSH$$aMicroglia: drug effects
000276798 650_2 $$2MeSH$$aMicroglia: metabolism
000276798 650_2 $$2MeSH$$aMicroglia: pathology
000276798 650_2 $$2MeSH$$aPyramidal Cells: drug effects
000276798 650_2 $$2MeSH$$aPyramidal Cells: metabolism
000276798 650_2 $$2MeSH$$aPyramidal Cells: pathology
000276798 650_2 $$2MeSH$$aInflammation: pathology
000276798 650_2 $$2MeSH$$aInflammation: metabolism
000276798 7001_ $$00000-0003-4749-5162$$aHenning, Lukas$$b1
000276798 7001_ $$00000-0003-2087-2984$$aFülle, Lorenz$$b2
000276798 7001_ $$00000-0003-2076-2160$$aKnöpper, Konrad$$b3
000276798 7001_ $$aBöhringer, Jana$$b4
000276798 7001_ $$0P:(DE-2719)9000563$$aGraelmann, Frederike$$b5
000276798 7001_ $$00000-0003-3964-6581$$aHänschke, Lea$$b6
000276798 7001_ $$aKenzler, Julia$$b7
000276798 7001_ $$0P:(DE-2719)2810593$$aBrosseron, Frederic$$b8
000276798 7001_ $$0P:(DE-2719)2000008$$aHeneka, Michael$$b9
000276798 7001_ $$00000-0002-7938-4814$$aDomingos, Ana I$$b10
000276798 7001_ $$00000-0002-1166-2355$$aEyerich, Stefanie$$b11
000276798 7001_ $$00000-0002-7979-5613$$aLochner, Matthias$$b12
000276798 7001_ $$00000-0002-3810-5890$$aWeighardt, Heike$$b13
000276798 7001_ $$00000-0003-0090-7553$$aBedner, Peter$$b14
000276798 7001_ $$00000-0003-2579-8357$$aSteinhäuser, Christian$$b15
000276798 7001_ $$00000-0002-7644-5642$$aFörster, Irmgard$$b16
000276798 773__ $$0PERI:(DE-600)2002194-X$$a10.1111/epi.18200$$gVol. 66, no. 2, p. 554 - 568$$n2$$p554 - 568$$tEpilepsia$$v66$$x0013-9580$$y2025
000276798 8564_ $$uhttps://pub.dzne.de/record/276798/files/DZNE-2025-00323.pdf$$yOpenAccess
000276798 8564_ $$uhttps://pub.dzne.de/record/276798/files/DZNE-2025-00323.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000276798 909CO $$ooai:pub.dzne.de:276798$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000276798 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810593$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b8$$kDZNE
000276798 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2000008$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b9$$kDZNE
000276798 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000276798 9141_ $$y2025
000276798 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-09
000276798 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-09
000276798 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-09
000276798 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-09
000276798 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-09
000276798 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEPILEPSIA : 2022$$d2024-12-09
000276798 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2024-12-09$$wger
000276798 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-12-09
000276798 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-09
000276798 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-09
000276798 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000276798 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000276798 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-09
000276798 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bEPILEPSIA : 2022$$d2024-12-09
000276798 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-09
000276798 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-09
000276798 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-09
000276798 9201_ $$0I:(DE-2719)1011303$$kAG Heneka$$lNeuroinflammation, Biomarker$$x0
000276798 980__ $$ajournal
000276798 980__ $$aVDB
000276798 980__ $$aUNRESTRICTED
000276798 980__ $$aI:(DE-2719)1011303
000276798 9801_ $$aFullTexts